

Jessica E. Thaxton, PhD, MsCR

Program Co-Leader, Cancer Cell Biology  
Lineberger Comprehensive Cancer Center  
Associate Professor  
Department of Cell Biology & Physiology

125 Mason Farm Road, Marsico Hall, 5229M/N  
University of North Carolina, Chapel Hill, 27514  
jess\_thaxton@med.unc.edu  
<https://www.thaxtonimmuno.com/>

## Education

---

NCI/NIH Paul Calabresi K12 Clinical Oncology Fellowship Hollings Cancer Center, Medical University of South Carolina ER Stress in T Cell Anti-Tumor Immunity	2016-2018
Medical University of South Carolina Masters of Clinical Research	2014
Department of Defense Breast Cancer Research Program Post-Doctoral Fellowship Knight Cancer Center, Oregon Health & Science University Hollings Cancer Center, Medical University of South Carolina Virus-specific T cell Responses in Breast Cancer Patients	2012-2015
NIH Ruth Kirschstein Fellowship Department of Microbiology & Immunology, Oregon Health & Science University Virus-specific T cells in Cancer Patients	2011-2012
Brown University Doctorate of Philosophy, <i>Magna Cum Laude</i> Pathobiology & Immunology	2009
Amherst College Bachelor of Arts Psychology, Pre-medical Studies	2001

## Professional Experience

---

Co-Leader, Cancer Cell Biology Program, Lineberger Comprehensive Cancer Center University of North Carolina, Chapel Hill, NC	2023-PRES.
Associate Professor, Department of Cell Biology & Physiology University of North Carolina, Chapel Hill, NC	2022-PRES.
Assistant Professor, Medical University of South Carolina, Charleston, SC Departments of Orthopedics, Microbiology & Immunology	2016-2021
Post-doctoral Fellow, Medical University of South Carolina, Charleston, SC Department of Microbiology & Immunology	2012-2015
Post-doctoral Fellow, Oregon Health & Sciences University, Portland, OR Department of Microbiology & Immunology Researched virus-specific T cells in breast cancer mouse models and patients	2010-2012
Graduate Student, Brown University, Providence, RI Department of Microbiology & Immunology	2004-2009
Research Specialist, Garvan Institute of Medical Research, Sydney, Australia Department of Allergy & Inflammation	2002-2004

Revised 10/01/2024

## Honors & Awards

---

2024	Co-Chair, Awards Review Committee, Society for Immunotherapy of Cancer
2024	Invited Speaker, American Society for Hematology Oncology, San Diego, CA
2024	Invited Keynote Speaker, Japanese Society of Immunology, Nagasaki, Japan
2024	Invited Speaker, Wake Forest Baptist Comprehensive Cancer Center, Wake Forest, NC
2024	Winship Elkin Lecturer, Emory University, Atlanta, GA
2024	Co-Chair, Translational Immune Oncology Study Section, NCI/NIH
2024	Invited Faculty, SITC Spring Scientific, Immunometabolism in Cancer Therapy, Miami, FL
2023	Standing Member, Translational Immune Oncology Study Section, NCI/NIH
2023	Invited Speaker, Agilent Technologies International Webinar Series
2023	Invited Speaker, Cancer Drug Discovery, Boston, MA
2022	Paper of the Year Award, Department of Cell Biology & Physiology, UNC-Chapel Hill
2021	Invited Speaker, Dana Farber Cancer Center, Boston, MA
2021	Invited Speaker, Lineberger Comprehensive Cancer Center, Chapel Hill, NC
2020	Invited Speaker, Tisch Brain Tumor Center, Duke University, Durham, NC
2020	Invited Speaker, New Mexico Comprehensive Cancer Center, Albuquerque, NM
2020	Co-Chair, Rapid Oral Sessions, Society for Immunotherapy of Cancer, National Meeting
2020	Chair, Meet the Expert Events, Society for Immunotherapy of Cancer, National Meeting
2019	Session Leader and Moderator, Society for Immunotherapy of Cancer, National Meeting
2018	Invited Speaker, Society for Immunotherapy of Cancer, National Meeting
2018	Sparkathon Winner, Team SITCure, Society for Immunotherapy of Cancer
2018	Selected to Sparkathon, Society for Immunotherapy of Cancer
2017	Selected to Immuno-oncology Young Investigators' Forum, Houston TX
2017	Dean's Nominee, AAMC Young Female Faculty Leadership Series
2017	Harper Drolet Award for Excellence in Sarcoma Research
2017	Young Investigator Award, Society for Immunotherapy of Cancer
2016	NCI Paul Calabresi Clinical Oncology Fellowship
2013	ESMO Postdoctoral Travel Award, Brussels, Belgium
2012	Department of Defense Breast Cancer Research Fellowship Award
2011	Early Clinical Investigator Award, Oregon Health & Science University
2010	NIH Ruth Kirschstein NRSA Fellowship, Oregon Health & Science University
2009	SRI Graduate Travel Award, Philadelphia, PA
2008	ASRI Graduate Travel Award, Chicago, IL
2008	ASRI Outstanding New Investigator Award
2007	ISRI Graduate Travel Award, Rio de Janeiro Brazil
2007	Environmental Toxicology Award, Brown University
2006	1 <sup>st</sup> Place Research Retreat Presentation, Brown University

## Bibliography

---

### Submitted/ Under Review papers/articles:

1. William D. Green, Amber Gomez, Alec L. Plotkin, Brandon M. Pratt, Genevieve N. Mullins, Jennifer L. Modliszewski, Vasyl Zhabotynsky, Mark G. Woodcock, Jarred M. Green, Gabrielle Cannon, Carlton W. Anderson, Thanh Truc Pham, Nancy P. Kren, Wolfgang Beckabir, Kristina Whately, Scott Bang, Rania Tsahouridis, Xiuyu Cui, Peter E. Fecci, Michael F. Coleman, Stephen D. Hursting, Yuliya Pylayeva-Gupta, **Jessica E. Thaxton**, Chad V. Pecot, Matthew E. Pipkin, Gianpietro Dotti H Shelton Earp, John P. Morris IV, Albert S. Baldwin, Natalie Stanley, J. Justin Milner. (2024), Molecular architecture of CD8 T cell adaptation to tissue and tumor microenvironments, In Revision, Immunity. 1-35 pages.
2. H. Kay Chung, Cong Liu, Alex Jambor, Brian P. Riesenber, Ming Sun, Eduardo Casillas, Brent Chick, Jun Wang, Shixin Ma, Bryan Mcdonald, Peixiang He, Qiyuan Yang, Timothy Chen, Siva Karthik Varanasi, Michael LaPorte, Thomas Mann, Dan Chen, Filipe Hoffmann, Victoria Tripple, Josephine Ho, Ukrae H. Cho, April Williams, Longwei Liu, Yingxiao Wang, Diana Hargreaves, **Jessica E. Thaxton**, Susan M.

Kaech, Wei Wang. Multi-Omics Atlas-Assisted Discovery of Transcription Factors for Selective T Cell State Programming. Under Review, Nature. 1-43 pages.

3. Coral del Mar Alicea Pauneto, Brian P. Riesenber, Evelyn J. Gandy, Andrew S. Kennedy, Katie E. Hurst, Jared Michael Green, Sinead Beausang, Elizabeth G. Hunt, Genevieve Clutton, Brian C. Miller, Robert J. Esther, Jennifer Modliszewski, Jennifer L. Guerriero, David Soto-Pantoja, Stergios J. Moschos, Michael Coleman, Justin J. Milner, R. Luke Wiseman, Jessica E. Thaxton. (2024), The Tumor Microenvironment Co-opts ATF4 in CD8<sup>+</sup> TILs to Obstruct Response to Immune Checkpoint Blockade Therapy, In Preparation. 1- 44 pages.

Published refereed papers/articles:

4. Hunt EG, Hurst KE, Riesenber BP, Kennedy AS, Gandy EJ, Andrews AM, Alicea Pauneto CDM, Ball LE, Wallace ED, Gao P, Meier J, Serody JJ, Coleman MF, **Thaxton JE**. Acetyl-CoA Carboxylase Obstructs CD8<sup>+</sup> T-Cell Lipid Utilization in the Tumor Microenvironment. Cell Metabolism. 2024 Mar 11:S1550-4131(24)00055-X. doi: 10.1016/j.cmet.2024.02.009.
5. Rangel Rivera GO, Dwyer CJ, Knochelmann HM, Smith AS, Aksoy BA, Cole AC, Wyatt MM, Kumaresan S, **Thaxton JE**, Lesinski GB, Paulos CM. Progressively enhancing stemness of adoptively transferred T cells with PI3K $\delta$  blockade improves metabolism and anti-tumor immunity. Cancer Research. 2024 Jan 2;84(1):69-83.
6. Riesenber BP, Hunt EG, Andrews AM, Hurst KE, Tennant MD, Leddy LR, Neskey DM, Hill EG, Gao P, Ball LE, **Thaxton JE**. Stress-mediated translation attenuation undermines T cell tumor control. Cancer Research. 2022 Dec 2;82(23):4386-4399. doi: 10.1158/0008-5472.CAN-22-1744. PMID: 36126165.
7. Hunt EG, Andrews AM, Larsen S, **Thaxton JE**. The ER-mitochondria Interface as a Dynamic Hub for T Cell Efficacy in Solid Tumors. Frontiers in Cell and Developmental Biology. 2022 Apr 27; 10:867341. doi:10.3389/fcell.2022.867341. PMID: 35573704.
8. Smith AS, Knochelmann HM, Wyatt MM, Dwyer CJ, Rangel Rivera GO, Rivera Reyes AM, **Thaxton JE**, Bartee EC, Rubinstein MP, Liu B, Paulos CM. B cells imprint adoptively transferred CD8<sup>+</sup> T cells with enhanced tumor immunity. Journal of Immunotherapy of Cancer. 2022 Jan;10(1):e003078. doi: 10.1136/jitc-2021-003078.PMID: 35017148
9. Wallace K, El Nahas GJ, Bookhout C, **Thaxton JE**, Lewin DN, Nikolaishvili-Feinberg N, Cohen SM, Brazeal JG, Hill EG, Wu JD, Baron JA, Alekseyenko AV. Immune responses vary in preinvasive colorectal lesions by tumor location and histology. cancer. Cancer Prevention Research. 2021 Sep;14(9):885-892. doi: 10.1158/1940-6207.CAPR-20-0592. PMID: 34341013
10. Rangel Rivera GO, Smith AS, Knochelmann HM, Wyatt MM, Dwyer CJ, Rivera Reyes AM, **Thaxton JE**, Paulos CM. Fundamentals of T cell metabolism and strategies to enhance cancer immunotherapy. Frontiers in Immunology. 2021 Mar 18;12:645242. doi: 10.3389/fimmu.2021.645242. PMID: 33815400.
11. Thomas U. Marron, MD, PhD, Aideen E. Ryan, PhD, Sangeetha M. Reddy, MD, Msci, Sabina Kaczanowska, PhD, Rania H. Younis, BDS, MDS, PhD, Dipti Thakkar, PhD, Jiajia Zhang, MD, MPH, Todd Bartkowiak, PhD, Rachel Howard, PhD, Kristin G. Anderson, PhD, Daniel Olson, MD, Abdul Rafeh Naqash, MD, Ravi B. Patel, MD, PhD, Esha Sachdev, MD, María Esperanza Rodríguez-Ruiz, MD, PhD, Michal Sheffer, PhD, Sarah E. Church, PhD<sup>18</sup>, Christopher Fuhrman, PhD<sup>18</sup>, Abigail Overacre-Delgoffe, PhD<sup>19</sup>, Rosa Nguyen, MD, PhD<sup>13</sup>, Vaia Florou, MD, **Jessica E. Thaxton, PhD**, David H. Aggen, MD, PhD and Jennifer L. Guerriero, PhD: Considerations for treatment duration in responders to immune checkpoint immunotherapy. Journal of Immunotherapy of Cancer; 2021 Mar;9(3):e001901. PMID: 33653801.

12. Mehta A, Cheney EM, Hartl C, Pantelidou C, Oliwa M, Castrillon JA, Lin J-R, Hurst, KE, Taveira M, Johnson NT, Oldham WM, Kalocsay M, Berberich MJ, Boswell SA, Kothari A, Johnson S, Dillon DA, Lipschitz M, Rodig S, Santagata S, Garber JE, Tung N, **Thaxton JE**, Mittendorf EA, Sorger PK, Shapiro GI, Guerriero JL. Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in BRAC1-associated triple-negative breast cancer. *Nature Cancer*. 2020 Dec; 2, 66-82.
13. Andrews AM, Tennant MD, **Thaxton JE**. Stress relief for cancer immunotherapy: Implications for the ER stress response in tumor immunity. *Cancer Immunology and Immunotherapy*. 2020 Oct 26; doi: 10.1007/s00262-020-02740-3. PMID: 33104836.
14. Halbert CH, Jefferson MS, Danielson C, Froeliger B, Giordano A, **Thaxton JE**. An observational study and randomized trial of stress reactivity in cancer disparities. *Health Psychology*. 2020 Sep;39(9):745-757. doi: 10.1037/hea0000882. PubMed PMID: 32833476.
15. Dwyer CJ, Arhontoulis DC, Rangel Rivera GO, Knochelmann HM, Smith AS, Wyatt MM, Rubinstein MP, Atkinson C, **Thaxton JE**, Neskey DM, Paulos CM. Ex vivo blockade of PI3K gamma or delta signaling enhances the antitumor potency of adoptively transferred CD8<sup>+</sup>T cells. *European Journal of Immunology*. 2020 May 8;. doi: 10.1002/eji.201948455. [Epub ahead of print] PubMed PMID: 32383488.
16. Hurst KE, Lawrence KA, Robino RA, Ball LE, Chung D, **Thaxton JE**. Remodeling Translation Primes CD8<sup>+</sup>T-cell Antitumor Immunity. *Cancer Immunology Research, Priority Brief*. 2020 May;8(5):587-595. doi: 10.1158/2326-6066.CIR-19-0516. Epub 2020 Feb 19. PubMed PMID: 32075802.
17. Hurst KE, Lawrence KA, Reyes Angeles L, Ye Z, Zhang J, Townsend DM, Dolloff N, **Thaxton JE**. Endoplasmic Reticulum Protein Disulfide Isomerase Shapes T Cell Efficacy for Adoptive Cellular Therapy of Tumors. *Cells*. 2019 Nov 26;8(12). doi: 10.3390/cells8121514. PubMed PMID: 31779147; PubMed Central PMCID: PMC6953024.
18. Hurst KE, Lawrence KA, Essman MT, Walton ZJ, Leddy LR, **Thaxton JE**. Endoplasmic Reticulum Stress Contributes to Mitochondrial Exhaustion of CD8<sup>+</sup>T Cells. *Cancer Immunology Research*. 2019 Mar;7(3):476-486. doi: 10.1158/2326-6066.CIR-18-0182. Epub 2019 Jan 18. PubMed PMID: 30659052; PubMed Central PMCID: PMC6397687.
19. **Thaxton JE**, Wallace C, Riesenber B, Zhang Y, Paulos CM, Beeson CC, Liu B, Li Z. Modulation of Endoplasmic Reticulum Stress Controls CD4<sup>+</sup>T-cell Activation and Antitumor Function. *Cancer Immunology Research*. 2017 Aug;5(8):666-675. doi: 10.1158/2326-6066.CIR-17-0081. Epub 2017 Jun 22. PubMed PMID: 28642246; PubMed Central PMCID: PMC5585019.
20. Ansa-Addo EA, **Thaxton JE**, Hong F, Wu BX, Zhang Y, Fugle CW, Metelli A, Riesenber B, Williams K, Gewirth DT, Chiosis G, Liu B, Li Z. Clients and Oncogenic Roles of Molecular Chaperone gp96/grp94. *Current Topics in Medicinal Chemistry*. 2016;16(25):2765-78. doi: 10.2174/1568026616666160413141613. Review. PubMed PMID: 27072698; PubMed Central PMCID: PMC5041304.
21. Zhang Y, Wu BX, Metelli A, **Thaxton JE**, Hong F, Rachidi S, Ansa-Addo E, Sun S, Vasu C, Yang Y, Liu B, Li Z. GP96 is a GARP chaperone and controls regulatory T cell functions. *Journal of Clinical Investigation*. 2015 Feb;125(2):859-69. doi: 10.1172/JCI79014. Epub 2015 Jan 20. PubMed PMID: 25607841; PubMed Central PMCID: PMC4319419.
22. **Thaxton JE**, Liu B, Zheng P, Liu Y, Li Z. Deletion of CD24 impairs development of heat shock protein gp96-driven autoimmune disease through expansion of myeloid-derived suppressor cells. *Journal of Immunology*. 2014 Jun 15;192(12):5679-86. doi: 10.4049/jimmunol.1302755. Epub 2014 May 7. PubMed PMID: 24808359; PubMed Central PMCID: PMC4185284.

23. **Thaxton JE**, Li Z. To affinity and beyond: harnessing the T cell receptor for cancer immunotherapy. *Human Vaccine and Immunotherapeutics*. 2014;10(11):3313-21. doi: 10.4161/21645515.2014.973314. Review. PubMed PMID: 25483644; PubMed Central PMCID: PMC4514023.
24. **Thaxton JE**, Nevers T, Lippe EO, Blois SM, Saito S, Sharma S. NKG2D blockade inhibits poly(I:C)-triggered fetal loss in wild type but not in IL-10<sup>-/-</sup> mice. *Journal of Immunology*. 2013 Apr 1;190(7):3639-47. doi: 10.4049/jimmunol.1203488. Epub 2013 Mar 1. PubMed PMID: 23455498; PubMed Central PMCID: PMC3608719.
25. **Thaxton JE**, Nevers TA, Sharma S. TLR-mediated preterm birth in response to pathogenic agents. *Infect Dis Obstet Gynecol*. 2010;2010. doi: 10.1155/2010/378472. Epub 2010 Aug 23. Review. PubMed PMID: 20827416; PubMed Central PMCID: PMC2933901.
26. **Thaxton JE**, Sharma S. Interleukin-10: a multi-faceted agent of pregnancy. *American Journal of Reproductive Immunology*. 2010 Jun;63(6):482-91. doi: 10.1111/j.1600-0897.2010.00810.x. Epub 2010 Feb 16. Review. PubMed PMID: 20163400; PubMed Central PMCID: PMC3628686.
27. **Thaxton JE**, Romero R, Sharma S. TLR9 activation coupled to IL-10 deficiency induces adverse pregnancy outcomes. *Journal of Immunology*. 2009 Jul 15;183(2):1144-54. doi: 10.4049/jimmunol.0900788. Epub 2009 Jun 26. PubMed PMID: 19561095; PubMed Central PMCID: PMC2785500.
28. Walters S, Webster KE, Sutherland A, Gardam S, Groom J, Liuwantara D, Mariño E, **Thaxton JE**, Weinberg A, Mackay F, Brink R, Sprent J, Grey ST. Increased CD4<sup>+</sup>Foxp3<sup>+</sup> T cells in BAFF-transgenic mice suppress T cell effector responses. *Journal of Immunology*. 2009 Jan 15;182(2):793-801. doi: 10.4049/jimmunol.182.2.793. PubMed PMID: 19124722.

## Mentor Activities

---

### Primary Mentor Graduate Students:

2022-PRES Andrew Kennedy	Manipulation of ER Architecture to Improve CAR-T Therapy in Cancers
2022-PRES Coral Alicea Pauneto	ATF4 as A Driver of T Cell Inefficacy in Tumors
2021-PRES Elizabeth Hunt	ER Dysmorphia Underlies T Cell Dysfunction in Cancers

### Primary and Secondary Mentorship, Postdoctoral & Junior Faculty:

2024-PRES Primary Mentor, Annaleigh Powell, PhD	SPIRE Postdoc Fellow, UNC Chapel Hill
2022-PRES Primary Mentor, Brian Riesenber, PhD	Postdoc Fellow & MBA Candidate, UNC Chapel Hill
2023-PRES Mentor, Brian Miller, MD, PhD	Melanoma Research Foundation Award
2023-PRES Mentor, Jeremy Meier, MD, PhD	America Society of Hematology Award

### Graduate Student Committees:

2024-PRES Committee Chair, Amber Gomez (Milner Lab)
2022-PRES Committee Chair, Matthew Zimmerman (Miller Lab)
2023-PRES Committee Member, Hannah Milan (Hursting Lab)
2023-PRES Committee Member, Amanda Linke (Perou Lab)
2023-PRES Committee Member, Rachel Dumez (Dowen Lab)
2022-PRES Committee Member, Shelly Pan (Serody Lab)
2022-PRES Committee Member, Allison Woods Taylor (Pecot & Vincent Labs)

## Grants

---

### Active Grants:

5-P30-CA016086-43	06/01/1997 - 11/30/2025
Cancer Center Support Grant	13,812\$

Revised 10/01/2024



PI: Earp  
Role: Co-Investigator (Program Co-Leader)

3R01CA244361-05S1, NIH/NCI 07/01/2023-06/30/2025  
ATF4 As a Driver of T Cell Inefficacy in Tumors 174,432\$  
Role: Principal Investigator, Supplement

LCCC Tier 2 Innovation Award 01/01/23 – 12/31/24  
Remodeling Th/Tc17 CAR-T Cell Biology to Enhance Efficacy in Solid Cancers 150,000\$  
Role: Co-Principal Investigator

R37 CA269499-01, NIH/NCI 04/01/2022-03/31/2027  
Immunometabolic pathways enabled by PARP inhibition in breast cancer 143,806\$  
PI: Guerriero  
Role: Co-Investigator

R01CA244361-01A1, NIH/NCI 07/01/2020-06/30/2025  
Targeting Chronic ER Stress in T Cells to Improve Immunotherapy 1,143,750\$  
Role: Principal Investigator

R01 CA248359-01, NIH/NCI 04/01/2020-03/31/2025  
Cancer Moonshot Initiative on Immunometabolism 1,140,605\$  
Exploitation of ER Stress Induced Immune Dysfunction to Improve Immunotherapy  
Role: Principal Investigator

#### NOA Pending:

R01CA288976-01A1, NIH/NCI, **3% score** 09/01/2024-08/31/2029  
Manipulating Lipid Metabolism to Reverse Immune Dysfunction in Solid Cancers 2,105,180\$  
Role: Principal Investigator

#### Pending Grants:

R01 CA248359-01, NIH/NCI 04/01/2025-03/31/2030  
Endoplasmic Reticulum Dynamics as a Determinant of T Cell Function in Cancer 2,403,257\$  
Role: Principal Investigator

R01 CA248359-01, NIH/NCI 04/01/2025-03/31/2030  
Metabolic Rewiring in IL-17-expressing T Cells Using Unconventional STING Agonism  
Role: Multi-Principal Investigator 2,492,766\$

#### Completed Grants:

R01CA226086-01A1, NIH/NCI 04/19/2019 - 03/31/2024  
The Immune Contexture of Colorectal Adenomas and Serrated Polyps 75,752\$  
PI: Wallace  
Role: Co-Investigator

MUSC Foundation for Research Development 01/01/2020-05/31/2021  
Development of ER Stress Inhibitors to augment cancer immunotherapy 49,538\$  
Role: Principal Investigator, 5% Effort

TEVA Pharmaceuticals 11/01/2019-10/31/2020  
Combination Therapy with Omacetaxine for Treatment of Solid Tumors 37,500\$  
Role: Principal Investigator

South Carolina Stress & Anti-Oxidants NIH COBRE Pilot 07/01/2019-08/31/2020  
Targeting ERO1a to Restore CD8 TIL Proteostasis 40,000\$

Role: Project Leader, 5% Effort

Hollings Cancer Center Clinical Concept Award  
Combination Therapy with Omacetaxine for Treatment of Solid Tumors  
Role: Principal Investigator

04/01/2019-03/31/2020  
50,000\$

NIH/NCI K12 Paul Calabresi Clinical Oncology Fellowship  
Targeting ER Stress for Cancer Immunotherapy  
Role: Trainee

01/01/2016-12/31/2018  
431,000\$

American Cancer Society Institutional Research Grant, Renewal  
Lone Survivor: Stressful Role of the ER in CD8<sup>+</sup> T cell metabolism  
Role: Project Leader

01/01/2017-12/31/2017  
35,000\$

American Cancer Society Institutional Research Grant  
Lone Survivor: Stressful Role of the ER in CD8<sup>+</sup> T cell metabolism  
Role: Project Leader

01/01/2016-12/31/2016  
30,000\$

Department of Defense Breast Cancer Research Post-Doctoral Fellowship  
Chemotherapy necessitates increased immune control of chronic HHVs  
Role: Principal Investigator

06/01/2012-05/31/2015  
450,000\$

Early Clinical Investigator Award, Oregon Health & Sciences University  
Chemotherapy necessitates increased immune control of chronic HHVs  
Role: Principal Investigator

01/01/2011-12/31/2011  
35,000\$

Environmental Toxicology National Training Grant, Brown University  
Department of Microbiology & Immunology  
Immunity in Fetal Tolerance and Loss  
Role: Trainee

2007-2009

GAANN National Training Grant, Brown University  
Department of Microbiology & Immunology  
Immunity in Fetal Tolerance and Loss  
Role: Trainee

2005-2007